ProteoNic Biosciences

ProteoNic 2G UNic Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

11 December 2025 -- Leiden, The Netherlands -- ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks for use in a project awarded to Ginkgo by the Biomedical Advanced Research and Development Authority (BARDA). The project,...

ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network

13 March 2024 -- Leiden, the Netherlands -- ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity. This strategic alliance will grant Ginkgo Bioworks’ customers access to ProteoNic's state of the art...
J.H. Oortweg 19-21 – 2333 CH Leiden – The Netherlands

+31 (0)71 332 27 27